Skip to main content

Table 1 Baseline clinicopathological characteristics of studied endometrial cancers cohorts

From: Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression

  Entire Cohort
N = 342
Group A
N = 215
Group B
N = 127
p *
Histology Endometrioid and non-endometrioid endometrial cancers Low- and moderate- grade endometroid endometrial cancer Non-endometrioid and high-grade endometroid endometrial cancer
Age [years] (mean ± SD**) 67.424 ± 8.399 65.167 ± 6.661 71.244 ± 9.599 < 0.0001#
BMI [kg/m2] (mean ± SD**) 24.945 ± 3.195 25.774 ± 3.488 23.542 ± 1.952 < 0.0001#
Stage*** < 0.0001#
 1 174 (50.88%) 133 (61.86%) 41 (32.28%)
 2 93 (27.19%) 45 (20.93%) 48 (37.80%)
 3 71 (20.76%) 35 (16.28%) 36 (28.35%)
 4 4 (1.17%) 2 (0.93%) 2 (1.57%)
Grade < 0.0001#
 1 90 (26.31%) 90 (41.86%) 0 (0.00%)
 2 132 (38.60%) 125 (58.14%) 7 (5.51%)
 3 120 (35.09%) 0 (0.00%) 120 (94.49%)
MI*** ≥ 50% 258 (75.44%) 148 (68.84%) 110 (86.61%) 0.0002#
+LN& 40 (11.70%) 15 (7.44%) 25 (19.68%) 0.0004#
+LVSI&& 94 (27.49%) 42 (19.53%) 52 (40.94%) < 0.0001#
+MELF&&& 18 (5.26%) 18 (8.37%) 0 (0.00%) < 0.0001#
Adjuvant therapy < 0.0001#
 VBTHA 175 (51.17%) 107 (49.77%) 68 (53.54%)
 ERTHB 26 (7.61%) 0 (0.00%) 26 (20.47%)
 CHTC 33 9.65%) 32 (14.88%) 1 (0.79%)
 HTHD 2 (0.58%) 2 (0.92%) 0 (0.00%)
 VBTHA + ERTHB 10 (2.92% 0 (0.00%) 10 (7.87%)
 ERTHB + CHTC 25 (7.31%) 3 (1.39%) 22 (17,33%)
 none 71 (20.76%) 71 (33.04%) 0 (0.00%)
Recurrence 46 (13.45%) 20 (9.30%) 26 (20.47%) 0.0034#
  1. * Comparison between Groups A and B; *SD – standard deviation; *** stage of disease according to the 2010 (FIGO) classification; ***MI - myometrial invasion; &LN - lymph node involvement; &&LVSI - lymphovascular space invasion; #statistically significant p-value; AVBTH – vaginal brachytherapy; BERTH – external radiotherapy; CCHT – chemotherapy; DHTH – hormonal therapy